This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?
The NeflgArd Part B Visual Abstract
Does targeted-release formulation of Budesonide improve kidney function in primary IgA Nephropathy? Check out the VA by NSMC Intern Anant Pilawan on NefIgArd part B trial
🤔 GWAS in IgA Nephropathy
Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy (Kiryluk, Nature Genetics 2023)
🤔 Sibeprenlimab in IgA Nephropathy
A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy (Mathur, NEJM 2024)
SPARE a Thought for SPARSENTAN?
PROTECT study on Sparsentan in IgAN - Visual Abstract
Is Sparsentan effective and safe for patients with IgAN on maximal Raas blockade? Check out the VA by NSMC intern Saumya Vishnoi
More options for immunosuppression in IgA....
Check out the tweetorial for the MAIN event - does MMF work in IgA Nephropathy?
MMF in IgA: Inching into the MAINstream?
Mycophenolate in IgAN - The Visual Abstract
Visual abstract for utility of MMF in IgAN by NSMC intern Dr Jeyakumar Meyyappan
IgA and steroids: the saga continues
Drug reps pitching you Nefecon? Catch-up with the RCT in our #TenTweetNephJC tweetorial
NefIgArdians of The Glomerular Galaxy
NefIgArd trial : Visual Abstract
Check out the Delightful Visual Abstract for the NefIgArd trial by Priti Meena
Ten Tweets does TESTING 2.0
Did you miss the TESTING reboot discussion? No worries, we have you covered here:
